Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 17 2020 - 7:55AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the month of December 2020
Commission
File Number 001-38716
GAMIDA
CELL LTD.
(Translation
of registrant’s name into English)
5
Nahum Heftsadie Street
Givaat
Shaul, Jerusalem 91340 Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Gamida
Cell Ltd.
On
December 16, 2020, Gamida Cell Ltd. (the “Company”) issued a press release announcing the commencement of a public
offering of its ordinary shares, a copy of which is furnished as Exhibit 99.1 to this Form 6-K.
Pursuant
to that certain Controlled Equity OfferingSM Sales Agreement, dated November 14, 2019 (the “Sales Agreement”),
between the Company and Cantor Fitzgerald & Co. (the “Agent”), the Company may offer and sell, from time to time,
shares of its common stock through the Agent in an “at the market offering” (each, an “ATM Offering”),
as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The
Company’s Registration Statement on Form F-3 (File No. 333-234701) included a sales agreement prospectus, pursuant to which
the Company may conduct such ATM Offerings for an aggregate offering price of up to $30.0 million (the “Sales Agreement
Prospectus”). The Company has not sold any shares under the Sales Agreement to date. The Company terminated the Sales Agreement
Prospectus on December 16, 2020, but the Sales Agreement remains in full force and effect. The Company will not make any sales
of its shares pursuant to the Sales Agreement unless and until a new sales agreement prospectus is filed.
This
report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-234701).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
GAMIDA
CELL LTD.
|
|
|
December
16, 2020
|
By:
|
/s/
Shai Lankry
|
|
|
Shai
Lankry
|
|
|
Chief
Financial Officer
|
2
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Apr 2024 to May 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From May 2023 to May 2024